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The decatenation checkpoint delays entry into mitosis until the chromosomes have been disentangled. Deficiency in or bypass of the
decatenation checkpoint can cause chromosome breakage and nondisjunction during mitosis, which results in aneuploidy and
chromosome rearrangements in the daughter cells. A deficiency in the decatenation checkpoint has been reported in lung and
bladder cancer cell lines and may contribute to the accumulation of chromosome aberrations that commonly occur during tumour
progression. A checkpoint deficiency has also been documented in cultured stem and progenitor cells, and cancer stem cells are likely
to be derived from stem and progenitor cells that lack an effective decatenation checkpoint. An inefficient decatenation checkpoint is
likely to be a source of the chromosome aberrations that are common features of most tumours, but an inefficient decatenation
checkpoint in cancer stem cells could also provide a potential target for chemotherapy.
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FUNCTION OF THE DECATENATION CHECKPOINT
Entanglements of sister chromatids are a consequence of DNA
replication, and nonreplicative catenations arise incidentally
during interphase (Gimenez-Abian et al, 2000). Gain and loss
of whole chromosomes and chromosome fragments result when
cells complete mitosis in the presence of entangled chromosomes
(Figure 1A). The G2 phase decatenation checkpoint delays entry
into mitosis until chromosomes have been decatenated (disen-
tangled) by topoisomerase II (topo II) (Downes et al, 1994). The
decatenation checkpoint is distinct from the DNA damage
checkpoint, the chromatin deacetylation checkpoint, the spindle
assembly checkpoint and other G2/M checkpoints.
Topoisomerase II enzymes disentangle chromosomes by passing
one double helix through a transient double-strand break (DSB) in
another double helix and then resealing the break. The classical
topo II inhibitors, which include etoposide (VP-16), teniposide
(VM-26), amsacrine, and adriamycin/doxorubicin, generate
massive numbers of DSBs and trigger the G2 phase DNA damage
checkpoint (Kaufmann and Kies, 1998). Studies with these topo II
poisons precluded the discovery of the decatenation checkpoint. In
contrast, the catalytic inhibitors, which include ICRF-193 and
related bisdioxopiperazines, inhibit topo II before DSB formation
and activate the decatenation checkpoint, but not the DNA damage
checkpoint (Downes et al, 1994; Roca et al, 1994). The decatena-
tion checkpoint is typically studied with the bisdioxopiperazine
topo II inhibitors.
CHECKPOINT DEFICIENCY AND CHROMOSOME
INSTABILITY
Deficiency in or bypass of the decatenation checkpoint can directly
result in chromosome instability because cells can complete
division in the presence of entangled chromosomes (Figure 1A).
Chromosome breakage and nondisjunction at anaphase leads to
chromosome translocations and other aberrations in daughter
cells. These chromosome imbalances have been observed in several
cell types following bisdioxopiperazine inhibition of topo II
(Gorbsky, 1994; Ishida et al, 1994; Deming et al, 2002; Damelin
et al, 2005). The spindle checkpoint would be expected to prevent
anaphase after failure or bypass of the decatenation checkpoint.
However, the spindle checkpoint is inefficient when the decatena-
tion checkpoint has failed. A possible explanation is that the
spindle checkpoint is not activated because the tension generated
by the chromosome entanglements is not distinguished from the
tension generated by amphitelic attachment (Damelin et al, 2005).
This idea is supported by the result that spindle checkpoint
activation in cohesin-deficient cells was relieved by the bisdioxo-
piperazine inhibition of topo II (Vagnarelli et al, 2004). It is also
possible that the spindle checkpoint delays cell cycle progression
only transiently and is eventually bypassed (Andreassen et al,
2003).
Specific types of genetic changes are predicted to result from an
inefficient decatenation checkpoint. The gain and loss of whole
chromosomes and chromosome fragments are expected, while
point mutations and mitotic recombination events are not. An
analysis of loss-of-heterozygosity (LOH) mutations found that in
mouse embryonic stem (ES) cells, the majority of LOH mutations
were attributable to nondisjunction, whereas in mouse embryonic
fibroblasts, LOH owing to nondisjunction was not observed
(Cervantes et al, 2002). The LOH events in ES cells are likely to
arise from the decatenation checkpoint deficiency in those cells.
CHECKPOINT STATUS IN CANCER CELLS
The decatenation checkpoint has been observed in many
mammalian cell types. The original report documented a
functional checkpoint in the Indian muntjac cells, PtK2 rat
kangaroo cells, Chinese hamster ovary cells, SV-MRC5-trans-
formed human fibroblasts, MSU1.1 v-myc-immortalised human
Received 3 August 2006; revised 17 November 2006; accepted 21
November 2006; published online 9 January 2007
*Correspondence: Professor TH Bestor; E-mail: THB12@columbia.edu
British Journal of Cancer (2007) 96, 201–205
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.comfibroblasts, and HeLa human cervical carcinoma cell lines (Downes
et al, 1994). Subsequently, the checkpoint was observed in human
lymphoblastoid cell lines (Deming et al, 2001), mouse embryonic
fibroblasts (Damelin et al, 2005), and primary cultures and strains
of human uroepithelial cells (Doherty et al, 2003) and human
fibroblasts (Kaufmann and Kies, 1998; Deming et al, 2001;
Franchitto et al, 2003; Damelin et al, 2005).
It was surprising to find that wild-type stem and progenitor cells
have an inherent deficiency in the decatenation checkpoint and
complete cell division in the presence of entangled chromosomes
(Damelin et al, 2005). The deficiency was documented in mouse
ES cells, mouse neural progenitors, and human CD34þ haema-
topoietic progenitors. When ES cells were induced to differentiate,
the efficiency of the checkpoint increased, which indicated that the
observed deficiency is a feature of the undifferentiated state.
A deficiency in the decatenation checkpoint has been reported
in bladder and lung cancer cells. The decatenation checkpoint was
found to be impaired in all five human bladder transitional cell
carcinoma lines tested (Doherty et al, 2003) and in three human
lung cancer cell lines, whereas three other lung cancer cell lines
exhibited normal decatenation checkpoint function (Nakagawa
et al, 2004). In these studies, there was a lack of correlation
between deficiency in the decatenation checkpoint and deficiency
in the other cell cycle checkpoints that were assessed.
WHY A DEFICIENCY IN STEM AND PROGENITOR
CELLS?
Although it seems paradoxical that stem and progenitor cells
should have a checkpoint deficiency and be susceptible to
increased genome instability, certain aspects of stem cell biology
must be considered in the context of cell cycle progression. Recent
studies have documented distinctive properties of nuclear
architecture and chromatin structure in stem cells (Azuara et al,
2006; Bernstein et al, 2006; Meshorer and Misteli, 2006). These
characteristics of stemness may not be compatible with an effective
decatenation checkpoint; in other words, it is possible that stem
cells cannot simultaneously maintain multipotency and the
decatenation checkpoint. For example, certain characteristics of
stem cell chromatin might mimic the molecular stimulus of the
checkpoint and would indiscriminately trigger the checkpoint if
the pathway were intact. Alternatively, expression of a factor that is
required for an efficient decatenation checkpoint might activate
other inappropriate signalling pathways in undifferentiated cells.
Another relevant aspect of stem cell biology – independent of
the first – is the heterogeneity, including the range of lifespan, of
the many types of cells that are termed stem cells. The stem and
progenitor cells that can be isolated and expanded in culture,
such as ES cells, embryonal germ (EG) cells, neural progenitors,
trophoblast stem cells, and CD34þ haematopoietic cells, are
derived from cell types that normally undergo only a few cell
divisions in vivo. In contrast, true stem cells, which have proved
difficult to isolate, are long-lived populations that replenish
specific cell lineages throughout the life of the organism. Transient
stem and progenitor cells undergo fewer cell divisions and are at
reduced risk of chromosome aberrations owing to an inefficient
decatenation checkpoint and may not be under selection for an
effective checkpoint; the incidence of chromosome aberrations
from the deficiency will be directly proportional to the number of
divisions that the cells undergo. A prediction of this model is that
long-lived stem cells have an efficient decatenation checkpoint,
whereas the transit amplifying stem and progenitor cells do not.
MOLECULAR MECHANISM OF THE DECATENATION
CHECKPOINT
The current understanding of the molecular control of the
decatenation checkpoint is outlined in Figure 1B. Decatenation
checkpoint signalling depends on ATR (ATM- and Rad3-related)
kinase, as overexpression of a dominant-negative ATR prevented
an efficient response (Deming et al, 2001). The checkpoint
response does not require ATM kinase (Deming et al, 2001).
Caffeine, which inhibits certain signalling molecules including
ATR, was shown to override the G2 delay (Downes et al, 1994).
ATR mediates the delay by inhibition of Plk1 (Polo-like kinase 1);
Plk1 activity was reduced following ICRF-193 treatment, and
conversely the checkpoint response was attenuated when active
Plk1 was overexpressed (Deming et al, 2002). During normal cell
cycle progression, Plk1 may phosphorylate cyclin B1 to cause the
nuclear localisation of cyclin B1/Cdk1 complexes and promote
mitosis. Expression of a constitutively nuclear cyclin B1 overrode
the decatenation checkpoint (Deming et al, 2002).
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Figure 1 (A) Mitosis in the presence of entangled chromosomes leads to aneuploidy. The decatenation checkpoint guards against nondisjunction and
chromosome breakage that occur when the cell enters mitosis before the chromosomes have been sufficiently decatenated by Topo II. (B) Working model
of decatenation checkpoint signalling. (C) Checkpoint deficiency in cancer cells could result in additional chromosome imbalances that increase tumour
malignancy (top). The presence of additional chromosome aberrations is represented by darker colour of the nucleus. Decatenation checkpoint deficiency is
an inherent feature of stem and progenitor cells and may lead to the formation of cancer stem cells (bottom). Chemotherapy that targets the decatenation
checkpoint may efficiently target cancer cells and CSCs.
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was observed in HCC1937 cells (which have a homozygous BRCA1
mutation) and the defect was reversed when wild-type BRCA1 was
expressed in those cells (Deming et al, 2001). Checkpoint activity
was found to be impaired in cells from four Werner Syndrome
patients and was restored when WRN (Werner helicase) was
expressed, which indicated a role for WRN in the decatenation
checkpoint (Franchitto et al, 2003). Werner helicase may be
required for the phosphorylation of BRCA1 in response to
entangled chromatids (Franchitto et al, 2003).
The molecular stimulus that activates the decatenation check-
point is not understood. One possibility is that a signal emanates
from sites of active decatenation, and mitotic entry is delayed until
the signal abates. It has been proposed that two factors that are
involved in checkpoint signalling, BRCA1 and WRN, function in
the decatenation process itself (Franchitto et al, 2003; Lou et al,
2005). A role for topo II itself in checkpoint signalling has also been
suggested (Gimenez-Abian et al, 2000). Alternatively, factors that
are not involved in decatenation could be sensitive to the degree of
chromosome entanglement and initiate checkpoint signalling.
Decatenation by topo II continues until the onset of anaphase,
and the poleward forces on the chromatids may be required to
drive decatenation to completion (Holm et al, 1985; Marians, 1987;
Uemura et al, 1987; Shamu and Murray, 1992). The decatenation
checkpoint therefore monitors the approach to completion, not the
full completion, of chromosome disentanglement (Downes et al,
1994). A similar threshold basis for checkpoint activation has
been documented for other cell cycle checkpoints, notably the
DNA replication checkpoint in which activation requires a certain
quantity of single-stranded DNA (Branzei and Foiani, 2005).
RELATIONSHIP WITH OTHER G2 PHASE
CHECKPOINTS
Several cell cycle checkpoints guard entry into mitosis or monitor
progression through mitosis, and each checkpoint is distinguish-
able from the others in terms of signalling components.
Observations at the cellular and molecular levels have distin-
guished the decatenation and DNA damage checkpoints. Bladder
and lung cancer cell lines exhibited different responses to ICRF-
193 treatment and irradiation (Doherty et al, 2003; Nakagawa
et al, 2004). In DM87 Indian muntjac cells, in which caffeine
cannot override the delay induced by irradiation or etoposide
treatment (for unknown reasons), caffeine did override the delay
induced by ICRF-193 treatment (Downes et al, 1994). Mouse ES
cells delayed entry into mitosis in response to etoposide treatment
but not ICRF-193 treatment (Damelin et al, 2005). The results with
DM87 and ES cells are particularly robust because opposite
responses were observed with ICRF-193 and etoposide, both of
which specifically inhibit topo II activity. If ICRF-193 does cause
any DNA damage, the amount of damage is insignificant by
comparison to the damage caused by topo II poisons and is below
the threshold that is necessary to trigger the DNA damage
checkpoint.
The decatenation checkpoint does not require ATM kinase
function, as the checkpoint was intact in cells from three ataxia
telangiectasia (A-T) patients with mutations in ATM (Deming et al,
2001). In contrast, the DNA damage checkpoint requires ATM and
was impaired in A-T cells. Phosphorylation of the Cds1 and Chk1
effector kinases was observed in lymphoblastoid lines following
DNA damage, but not after ICRF-193 treatment (Deming et al,
2001). In addition, Cdk1 activity was reduced in response to DNA
damage but not ICRF-193 treatment. These data revealed specific
differences in the signalling pathways of the decatenation and DNA
damage checkpoints.
It is important to consider the decatenation checkpoint in
comparison to a recently characterised ICRF-193-induced
metaphase arrest (Skoufias et al, 2004), which is probably distinct
from the decatenation checkpoint. It will be important to clarify
the relationship between the decatenation checkpoint (which
blocks entry into mitosis) and the metaphase arrest (during
mitosis), and to determine whether the metaphase arrest is a bona
fide checkpoint that involves active signalling or whether it reflects
a physical obstacle to chromatid segregation that is imposed by
chromosome entanglements (Clarke et al, 1993).
It has been proposed that the G2 delay induced by chromosome
entanglements is controlled by a more general antephase
checkpoint that responds to aberrant chromatin topology and is
mediated by p38 MAP kinase (Mikhailov et al, 2004). A prophase
delay can be induced by inhibitors of topo II, inhibitors of histone
deacetylases, and osmotic stress. However, chemical genetics
screens indicated that the decatenation checkpoint and chromatin
deacetylation checkpoint are distinct (Haggarty et al, 2003). It is
possible that p38 signalling is common to several G2/M
checkpoints that are distinguished by other signalling events.
One study proposed that p38 is an ‘early sensor’ for cell damage,
although only for certain types of stress or damage (Bulavin et al,
2001). The antephase checkpoint was proposed to be independent
of ATM and the DNA damage checkpoint yet was induced by
treatments that produced large quantities of DSBs (Mikhailov et al,
2004); if the damage and antephase checkpoints were independent,
then the damage checkpoint impairment in A-T cells (with
mutation in ATM) would be masked by the p38-mediated
response, but A-T cells consistently exhibit a checkpoint defect.
The various G2 checkpoints, including chromatin deacetylation,
DNA damage, and decatenation, may or may not involve p38
MAP kinase, but they are distinguished from one another by
other molecular components. The antephase checkpoint may
overlap with characterised checkpoints via p38 or may represent
the p38-dependent aspect of each of the characterised checkpoints.
Further studies are needed to address these issues.
THE DECATENATION CHECKPOINT AND CANCER
Chromosome aberrations – aneuploidy, heteroploidy, and re-
arrangements – have been documented in nearly all tumour types
and actively contribute to carcinogenesis (Sen, 2000), and such
aberrations could arise via an inefficient decatenation checkpoint.
The products of two tumour suppressor genes, BRCA1 and WRN,
have roles in decatenation checkpoint function, and mutations in
either gene may increase the likelihood of cancer in part because
of the checkpoint deficiency. Aneuploidy is a common feature of
BRCA1-associated cancers (Chappuis et al, 2000). Checkpoint
deficiency that is acquired during carcinogenesis, for example in
the lung and bladder cancer cell lines described above, may result
in additional genetic changes that contribute to tumour progres-
sion (Figure 1C).
The decatenation checkpoint has particular implications for
cancer in the context of stem cells and cancer stem cells (CSCs).
The CSC hypothesis stipulates that only a small subset of cells in a
tumour has the potential to drive tumour growth and progression
(Reya et al, 2001). Cancer stem cells have been isolated from
leukaemias and solid tumours and share many properties with
normal stem cells. Cancer stem cells could theoretically arise in
many ways, one of which is the transformation of a normal stem
cell. The inherent decatenation checkpoint deficiency in normal
stem and progenitor cells may constitute the basis for transforma-
tion and the earliest stages of carcinogenesis (Figure 1C). In
addition, it seems likely that CSCs, like their normal stem cell
counterparts, have a deficiency in the decatenation checkpoint,
and that this deficiency could lead to additional genetic changes
and increased tumour malignancy.
One potential manifestation of the relationship between the
decatenation checkpoint, stem cells, and cancer is the syndrome
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with CTM, a specific trisomy (e.g. trisomy 8) is found in a subset of
cells and a range of cell types, and the trisomy is projected back to
a mitotic error in a stem or progenitor cell. The CTM phenotype
varies broadly and presumably depends on the nature of the
particular stem or progenitor cell in which the trisomy originally
appeared. Patients with CTM have a predisposition to cancer,
notably haematological malignancy (Brady et al, 2000). One model
to explain these observations is that the trisomy in the stem or
progenitor cell arises from the decatenation checkpoint deficiency
in those cells. The imbalance could arise from any of a range of
deficiencies or spontaneous errors, but it is appealing to consider
the decatenation checkpoint because of its deficiency in wild-type
stem and progenitor cells.
The checkpoint deficiency in stem and progenitor cells also
reflects the potential for increased genetic instability in those cells
during ex vivo expansion, for example for stem cell therapy
(Damelin and Bestor, 2006). During expansion, stem cells are
forced to undergo many more rounds of cell division than they
normally do in vivo, and the nonphysiological expansion may
amplify inherent susceptibilities. Recurrent chromosome imbal-
ances have been documented in human and mouse embryonic
stem cells during laboratory culture (reviewed in Damelin and
Bestor, 2006). The introduction into a patient of a stem cell that
has acquired a genetic change could increase the patient’s risk of
cancer. Sources of genetic instability in stem cells during ex vivo
expansion must be understood in order to minimise the risks
involved (Kaufmann, 2006).
The decatenation checkpoint deficiency in lung and bladder
cancer cell lines and in stem and progenitor cells suggests that
factors that mediate the checkpoint could be useful targets for
chemotherapy. The clinical potential was highlighted by the
provocative finding that two lung cancer cell lines with a deficient
decatenation checkpoint exhibited increased sensitivity to ICRF-
193 (Nakagawa et al, 2004). Topoisomerase II poisons are
commonly used to treat certain cancers, but these inhibitors
target all dividing cells and are highly toxic. In contrast,
bisdioxopiperazines and other compounds that target the dec-
atenation checkpoint (Haggarty et al, 2003) may selectively target
cancer cells in some tumours. Risk–benefit analysis will be
necessary, as one potential side effect of targeting the decatenation
checkpoint could be the stimulation of chromosome imbalances in
otherwise normal stem and progenitor cells.
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